{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T03:38:12Z","timestamp":1786592292875,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Vaginal cancer is a rare gynecological malignant disease. In Japan, the proportion of vaginal cancer cases is estimated to increase as the population ages. The purpose of this study is to evaluate the age-specific incidence, treatment options, and prognosis of vaginal cancer in Japan.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study used the Japan Society of Obstetrics and Gynecology tumor registry database. Patient characteristics included age, year diagnosed with vaginal cancer (2016\u20132020), and cancer stages, histological types, and treatment methods. The 2016 and 2017 dataset included follow-up time, survival status, and cause of death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 746 patients were diagnosed with vaginal cancer from 2016 to 2020. The median age of the patients was 72\u00a0years. Radiotherapy was most chosen as the primary treatment option for all ages and stages. Surgery was selected mostly in stage I and II (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009118, 22.2% of these stage patients). Five-year overall survival for stages I, II, III, and IV was 87.6%, 55.6%, 59.9%, and 15.3%, respectively. Multivariate analysis showed that 3\u00a0year OS was significantly better for patients who underwent surgery than those who received chemotherapy (HR 3.11,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.00389) and those who received radiation therapy (HR 2.89,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0241), but not compared with concurrent chemoradiotherapy (HR 1.21,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.7091). Histological type did not significantly affect prognosis. For stages I and II, surgery resulted in a better prognosis than radiation (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.03).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Radiation therapy is the primary treatment for vaginal cancer; however, surgery may be an effective option in early-stage vaginal cancer when cases are appropriately selected.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03017-y","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:33:12Z","timestamp":1775748792000},"page":"947-956","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Survival and prognostic factors in vaginal cancer: an analysis of 2016\u20132020 nationwide data"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3683-0282","authenticated-orcid":false,"given":"Tatsuhiko","family":"Shigeto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Yamagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiko","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Kawana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Nagase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"3017_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.gore.2016.08.002","volume":"17","author":"S Damast","year":"2016","unstructured":"Damast S, Takiar V, McCarthy S et al (2016) Treatment of early stage vaginal cancer with EBRT and MRI-based intracavitary brachytherapy: a retrospective case review. Gynecol Oncol Rep 17:89\u201392. https:\/\/doi.org\/10.1016\/j.gore.2016.08.002","journal-title":"Gynecol Oncol Rep"},{"key":"3017_CR2","first-page":"10","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Gianquinto AN et al (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10\u201345","journal-title":"CA Cancer J Clin"},{"key":"3017_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088323","volume":"9","author":"M Nygard","year":"2014","unstructured":"Nygard M, Hansen BT, Dillner J et al (2014) Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and preinvasive neoplasia: establishing the baseline for surleillance. PLoS ONE 9:e88323","journal-title":"PLoS ONE"},{"key":"3017_CR4","first-page":"1033","volume":"83","author":"TC William","year":"1998","unstructured":"William TC, Phillips JL, Menck HR (1998) The National Cancer Data Base report on cancer of the vagina. Am Cancer Soc 83:1033\u20131040","journal-title":"Am Cancer Soc"},{"key":"3017_CR5","doi-asserted-by":"publisher","first-page":"373","DOI":"10.3892\/mco.2017.1158","volume":"6","author":"R Tasaka","year":"2017","unstructured":"Tasaka R, Fukuda T, Wada T et al (2017) A retrospective clinical analysis of 5 cases of vaginal melanoma. Mol Clin Oncol 6:373\u2013376. https:\/\/doi.org\/10.3892\/mco.2017.1158","journal-title":"Mol Clin Oncol"},{"key":"3017_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.ogc.2012.04.002","volume":"39","author":"JS Carter","year":"2012","unstructured":"Carter JS, Downs LS Jr. (2012) Vulvar and vaginal cancer. Obstet Gynecol Clin North Am 39:213\u2013231","journal-title":"Obstet Gynecol Clin North Am"},{"issue":"2","key":"3017_CR7","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ygyno.2013.08.012","volume":"131","author":"SM Hiniker","year":"2013","unstructured":"Hiniker SM, Roux A, Murphy JD et al (2013) Primary squamous cell carcinoma of the vagina: Prognostic factors, treatment patterns, and outcomes. Gynecol Oncol 131(2):380\u2013385","journal-title":"Gynecol Oncol"},{"key":"3017_CR8","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1111\/jog.12958","volume":"42","author":"N Akino","year":"2016","unstructured":"Akino N, Wada-Hiraike O, Matsumoto Y et al (2016) Vaginal cancer possibly caused by pessary and immunocompromised condition: Multiple risk factors may influence vaginal cancer development. J Obstet Gynaecol Res 42:748\u2013751. https:\/\/doi.org\/10.1111\/jog.12958","journal-title":"J Obstet Gynaecol Res"},{"key":"3017_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.883805","volume":"12","author":"SK Baral","year":"2022","unstructured":"Baral SK, Biswas P, Kaium MA et al (2022) A comprehensive discussion in vaginal cancer based on mechanisms, tratents, risk factors and prevention. Front Oncol 12:883805","journal-title":"Front Oncol"},{"key":"3017_CR10","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Vaginal Cancer, version 5. 2025. Retrieved from https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/vaginal.pdf."},{"issue":"3","key":"3017_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.5582\/bst.2024.01150","volume":"18","author":"Y Liu","year":"2024","unstructured":"Liu Y, Kobayashi S, Karako K et al (2024) The latest policies, practices, and hotspots in research in conjunction with the aging of Japan\u2019s population. Biosci Trends 18(3):219\u2013223","journal-title":"Biosci Trends"},{"issue":"3","key":"3017_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48(3):452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"3017_CR13","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1016\/S0140-6736(07)60777-6","volume":"369","author":"EA Joura","year":"2007","unstructured":"Joura EA, Leodolter S, Hernandez-Avila M et al (2007) Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet 369:1693\u20131702","journal-title":"Lancet"},{"issue":"11","key":"3017_CR14","doi-asserted-by":"publisher","first-page":"7091","DOI":"10.21037\/tcr-20-1825","volume":"9","author":"J Huang","year":"2020","unstructured":"Huang J, Cai M, Zhu Z (2020) Survival and prognostic factors in primary vaginal cancer: an analysis of 2004-2014 SEER data. Transl Cancer Res 9(11):7091\u20137102","journal-title":"Transl Cancer Res"},{"key":"3017_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.ygyno.2008.07.007","volume":"111","author":"J Lian","year":"2008","unstructured":"Lian J, Dundas G, Carlone M et al (2008) Twenty-year review of radiotherapy for vaginal cancer: an institutional experience. Gynecol Oncol 111:298\u2013306","journal-title":"Gynecol Oncol"},{"key":"3017_CR16","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1006\/gyno.2001.6171","volume":"81","author":"WA Tjalma","year":"2001","unstructured":"Tjalma WA, Monaghan JM, de Barros Lopes A et al (2001) The role of surgery in invasive squamous carcinoma of the vagina. Gynecol Oncol 81:360\u2013365","journal-title":"Gynecol Oncol"},{"key":"3017_CR17","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1097\/IGC.0b013e3182072e44","volume":"21","author":"AJ Ghia","year":"2011","unstructured":"Ghia AJ, Gonzalez VJ, Tward JD et al (2011) Primary vaginal cancer and chemoradiotherapy: a patterns-of-care analysis. Int J Gynecol Cancer 21:378\u2013384","journal-title":"Int J Gynecol Cancer"},{"key":"3017_CR18","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ijrobp.2004.09.032","volume":"62","author":"SJ Frank","year":"2005","unstructured":"Frank SJ, Jhingran A, Levenback C et al (2005) Definitive radiation therapy for squamous cell carcinoma of the vagina. Int J Radiat Oncol Biol Phys 62:138\u2013147","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3017_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.radonc.2007.09.015","volume":"85","author":"R de Crevoisier","year":"2007","unstructured":"de Crevoisier R, Sanfilippo N, Gerbaulet A et al (2007) Exclusive radiotherapy for primary squamous cell carcinoma of the vagina. Radiother Oncol 85:362\u2013370","journal-title":"Radiother Oncol"},{"key":"3017_CR20","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1097\/AOG.0b013e31819fe844","volume":"113","author":"CA Shah","year":"2009","unstructured":"Shah CA, Goff BA, Lowe K et al (2009) Factors affecting risk of mortality in women with vaginal cancer. Obstet Gynecol 113:1038\u20131045","journal-title":"Obstet Gynecol"},{"key":"3017_CR21","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ygyno.2014.09.018","volume":"135","author":"MS Rajagopalan","year":"2014","unstructured":"Rajagopalan MS, Xu KM, Lin JF et al (2014) Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a National Cancer Data Base (NCDB) study. Gynecol Oncol 135:495\u2013502","journal-title":"Gynecol Oncol"},{"key":"3017_CR22","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s13224-015-0697-6","volume":"66","author":"CG Prameela","year":"2016","unstructured":"Prameela CG, Ravind R, Gurram BC et al (2016) Prognostic Factors in Primary Vaginal Cancer: A Single Institute Experience and Review of Literature. J Obstet Gynaecol India 66:363\u2013371","journal-title":"J Obstet Gynaecol India"},{"key":"3017_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s10147-017-1193-z","volume":"23","author":"T Saito","year":"2018","unstructured":"Saito T, Tabata T, Ikushima H et al (2018) Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of vulvar cancer and vaginal cancer. Int J Clin Oncol 23:201\u2013234","journal-title":"Int J Clin Oncol"},{"key":"3017_CR24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1006\/gyno.1995.1008","volume":"56","author":"RG Stock","year":"1995","unstructured":"Stock RG, Chen AS, Seski J (1995) A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. Gynecol Oncol 56:43\u201352. https:\/\/doi.org\/10.1006\/gyno.1995.1008","journal-title":"Gynecol Oncol"},{"key":"3017_CR25","unstructured":"Chemoradiotherapy for cervical cancer meta- analysis collaboration (CCMAC). Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data mata-analysis. Cochrane Database Syst Rev 2010;1"},{"key":"3017_CR26","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ygyno.2014.09.018","volume":"135","author":"MS Rajagopalan","year":"2014","unstructured":"Rajagopalan MS, Xu KM, Lin JF (2014) Adoption and impact of concurrent chemoradiation therapy for vaginal cancer: a national cancer data base (NCDB) study. Gynecol Oncol 135:495\u2013502","journal-title":"Gynecol Oncol"},{"key":"3017_CR27","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1016\/j.ijrobp.2011.03.049","volume":"82","author":"JCA Dimopoulos","year":"2012","unstructured":"Dimopoulos JCA, Schmid MP, Fidarova E (2012) Treatment of locally advanced vaginal cancer with radiochemotherapy and magnetic resonance image-guided adaptive brachytherapy: dose-volume parameters and first clinical results. Int J Radiat Oncol Biol Phys 82:1880\u20131888","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"3017_CR28","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1046\/j.1440-1673.1999.00715.x","volume":"43","author":"F Foroudi","year":"1999","unstructured":"Foroudi F, Bull CA, Gebski V (1999) Primary invasive cancer of the vagina: outcome and complications of therapy. Australas Radiol 43:472\u2013475","journal-title":"Australas Radiol"},{"key":"3017_CR29","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1048-891x.2004.014066.x","volume":"14","author":"JL Dalrymple","year":"2004","unstructured":"Dalrymple JL, Russell AH, Lee SW (2004) Chemoradiation for primary invasive squamous carcinoma of the vagina. Int J Gynecol Cancer 14:110\u2013117","journal-title":"Int J Gynecol Cancer"},{"key":"3017_CR30","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.ygyno.2016.03.011","volume":"141","author":"A Orton","year":"2016","unstructured":"Orton A, Boothe D, Williams N (2016) Brachytherapy improves survival in primary vaginal cancer. Gynecol Oncol 141:501\u2013506","journal-title":"Gynecol Oncol"},{"key":"3017_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.brachy.2020.08.020","volume":"20","author":"LB Reshko","year":"2021","unstructured":"Reshko LB, Gaskins JT, Metzinger DS (2021) The impact of brachytherapy boost and radiotherapy treatment duration on survival in patients with vaginal cancer treated with definitive chemoradiation. Brachytherapy 20:75\u201384","journal-title":"Brachytherapy"},{"key":"3017_CR32","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.ygyno.2020.08.036","volume":"159","author":"J Yang","year":"2020","unstructured":"Yang J, Delara R, Magrina J (2020) Management and outcomes of primary vaginal cancer. Gynecol Oncol 159:456\u2013463","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03017-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03017-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03017-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T16:53:11Z","timestamp":1779727991000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03017-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3017"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03017-y","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"28 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have no conflicts of interest in relation to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}